Results 71 to 80 of about 2,558,154 (306)
Training toolkit on drug policy advocacy.
, 2013 This training toolkit has been developed by the International Drug Policy Consortium (IDPC) and the Eurasian Harm Reduction Network (EHRN) to build the capacity of civil society organisations for engaging with, and influencing, drug policy making ...
core
Impact of Scotland's smoke-free legislation on pregnancy complications: retrospective cohort study [PDF]
, 2012 <b>Background:</b> Both active smoking and environmental tobacco smoke exposure are associated with pregnancy complications. In March 2006, Scotland implemented legislation prohibiting smoking in all wholly or partially enclosed public ...
Mackay Daniel F. +15 more
core +2 more sources
British Journal of Clinical Pharmacology, EarlyView.Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley +1 more source
‘Civil society involvement in drug policy’ webinar.
, 2018 On 30th November 2018, Ana Liffey Drug Project hosted a webinar about Civil Society Involvement in Drug Policy. The event included interviews with: Anna Quigley (CityWide) Tony Duffin (Ana Liffey Drug Project) Aoife Frances (National Family Support ...
core
Taking stock: A decade of drug policy - A civil society shadow report. [PDF]
, 2018 Taking stock: A decade of drug policy’ evaluates the impacts of drug policies implemented across the world over the past decade, using data from the United Nations (UN), complemented with peer-reviewed academic research and grey literature reports from ...
core
Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics
British Journal of Clinical Pharmacology, EarlyView.Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay +5 more
wiley +1 more source
The effects of state rules on opioid prescribing in Indiana
BMC Health Services Research, 2018 Background Prescription opioids have been linked to over half of the 28,000 opioid overdose deaths in 2014. High rates of prescription opioid non-medical use have continued despite nearly all states implementing large-scale prescription drug monitoring ...
Morhaf Al Achkar +5 more
doaj +1 more source
Ohio BWC Drug-Free EZ Program : technical assistance manual : reference/resource guide
, 2002 Title from title screen (viewed Sept. 24, 2004).; "BWC-7648 (Rev. 7/18/2002)"--Screen 87 (i.e. p. 1 of form: Progress report, Drug-Free Workplace/Drug-Free EZ Program).; Electronic text (pdf, 89 p.).; Harvested from the web on 9/24 ...
Drug-Free EZ Program (Ohio. Bureau of Workers' Compensation)
core
British Journal of Clinical Pharmacology, EarlyView.Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden +3 more
wiley +1 more source
Zuranolone: A case study in (regulatory) rush to judgement?
British Journal of Clinical Pharmacology, EarlyView.Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove +4 more
wiley +1 more source